Graham brings to Filamon a lifetime career in cancer research and drug development, along with a wealth of public company corporate experience spanning three decades in Australia, U.K. and U.S.
His Doctorate of Philosophy (Faculty of Medicine, The University of Sydney) was awarded for the manufacture of a novel immunosuppressive drug for the treatment of kidney transplant recipients. Twenty-two years of cancer research then followed, before the establishment of his first company, Novogen Limited (now Kazia Therapeutics), in 1994. That was followed by the establishment of an additional three exchange-listed biotechnology companies, at various times serving as Chairman, CEO and Director of all four companies, all of which currently remain operational.
- Novogen Ltd (now Kazia Therapeutics) (ASX: KZA; Nasdaq: KZIA) listed 1994
- MEI Pharma Inc (Nasdaq: MEIP) listed 2002
- Noxopharm Ltd (ASX: NOX) listed 2016
- Nyrada Inc (ASX: NYR) listed 2020
Both as a medical researcher and cancer survivor, Graham has made it his life’s mission to better understand the underlying mechanisms that allow cancers to survive and flourish in the body, on the basis that understanding those mechanisms is the critical step in finding effective treatments. It was the approaches being taken by Professors de Souza and Scott (role of inflammation in driving tumour aggression) and Henry Ford Health (role of genetic drivers of tumour aggression and drug resistance) that attracted him to become involved in Filamon.